Dimensional Fund Advisors LP Has $211.35 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Dimensional Fund Advisors LP increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 6.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,000,838 shares of the medical equipment provider's stock after buying an additional 126,151 shares during the quarter. Dimensional Fund Advisors LP owned approximately 1.01% of Zimmer Biomet worth $211,348,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Franklin Resources Inc. lifted its stake in Zimmer Biomet by 398.7% in the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after purchasing an additional 2,796,372 shares during the last quarter. Norges Bank acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $216,223,000. Dodge & Cox boosted its stake in shares of Zimmer Biomet by 12.0% during the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock worth $2,019,480,000 after acquiring an additional 2,044,645 shares during the period. Sound Shore Management Inc. CT acquired a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $81,447,000. Finally, FMR LLC raised its stake in Zimmer Biomet by 91.6% in the 4th quarter. FMR LLC now owns 1,438,011 shares of the medical equipment provider's stock valued at $151,897,000 after acquiring an additional 687,675 shares during the period. 88.89% of the stock is owned by institutional investors.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.95% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Stifel Nicolaus upped their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a report on Thursday, January 23rd. BTIG Research reaffirmed a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Raymond James cut their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Barclays lowered their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Monday, February 10th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of "Hold" and an average target price of $124.15.

Zimmer Biomet Price Performance

ZBH stock traded up $0.08 during midday trading on Monday, reaching $101.59. 185,739 shares of the stock were exchanged, compared to its average volume of 1,663,936. Zimmer Biomet Holdings, Inc. has a 52 week low of $93.10 and a 52 week high of $123.96. The company has a fifty day moving average price of $105.81 and a 200 day moving average price of $106.61. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock has a market capitalization of $20.10 billion, a PE ratio of 22.87, a P/E/G ratio of 1.95 and a beta of 0.84.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the company earned $2.20 earnings per share. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.95%. Zimmer Biomet's dividend payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.